导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -4.13% | 3214/4773 |
| 近一周 | -2.67% | 2799/5462 |
| 近一月 | -2.95% | 1475/5421 |
| 近一季 | -3.29% | 1386/5209 |
| 近半年 | -6.11% | 3014/4920 |
| 近一年 | -5.90% | 3168/4366 |
| 近两年 | 24.49% | 2523/2954 |
| 近三年 | 6.37% | 1814/2253 |
| 成立以来 | 62.25% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-3.10% 3036/4961 |
1.20% 3064/5312 |
- - |
- - |
| 2025 | 6.49% 2960/4813 |
-0.90% 2454/3635 |
-2.41% 3349/4076 |
13.51% 2985/4524 |
-3.00% 3240/4813 |
| 2024 | 12.97% 1195/3463 |
3.51% 556/2808 |
-2.56% 1204/3014 |
18.67% 965/3129 |
-5.62% 2575/3463 |
| 2023 | -7.01% 888/2656 |
4.57% 918/2280 |
-4.85% 1309/2385 |
0.51% 363/2515 |
-7.02% 2017/2655 |
| 2022 | -17.39% 586/2207 |
-9.78% 345/1919 |
1.82% 1415/2016 |
-12.08% 638/2113 |
2.28% 989/2208 |
| 2021 | -4.96% 967/1822 |
0.82% 275/1255 |
-1.15% 1159/1330 |
-3.62% 649/1466 |
-1.05% 1302/1822 |
| 2020 | 25.46% 619/1250 |
-12.55% 892/1028 |
11.47% 728/1067 |
11.22% 466/1164 |
15.72% 194/1184 |
| 2019 | 51.76% 93/1092 |
35.26% 93/739 |
0.42% 166/788 |
0.12% 555/850 |
11.59% 54/918 |
| 2018 | - - |
- - |
- - |
- - |
-8.43% 93/682 |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 建信深证基本面60ETF联接C VS. 长安沪深300非周期A(740101) |